ArticleCureus2024

Safety and Effectiveness of Liv.52 DS in Patients With Varied Hepatic Disorders: An Open-Label, Multi-centre, Phase IV Study.

Sachin K Shivnitwar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.